Leede Financial lowered shares of Oncolytics Biotech (NASDAQ:ONCY - Free Report) from a strong-buy rating to a moderate buy rating in a research note issued to investors on Wednesday morning,Zacks.com reports.
Separately, HC Wainwright restated a "buy" rating and set a $5.00 price objective on shares of Oncolytics Biotech in a research note on Thursday.
Check Out Our Latest Analysis on ONCY
Oncolytics Biotech Stock Performance
NASDAQ ONCY traded down $0.03 on Wednesday, reaching $0.98. The company had a trading volume of 245,358 shares, compared to its average volume of 328,224. The firm has a market capitalization of $75.53 million, a price-to-earnings ratio of -3.63 and a beta of 1.69. Oncolytics Biotech has a 1-year low of $0.84 and a 1-year high of $1.75. The company's fifty day moving average is $1.09 and its 200-day moving average is $1.06.
Institutional Investors Weigh In On Oncolytics Biotech
A hedge fund recently bought a new stake in Oncolytics Biotech stock. Virtu Financial LLC bought a new stake in Oncolytics Biotech Inc. (NASDAQ:ONCY - Free Report) during the first quarter, according to its most recent disclosure with the SEC. The institutional investor bought 51,889 shares of the company's stock, valued at approximately $55,000. Virtu Financial LLC owned 0.07% of Oncolytics Biotech as of its most recent filing with the SEC. 6.82% of the stock is currently owned by institutional investors and hedge funds.
About Oncolytics Biotech
(
Get Free Report)
Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.
See Also
Before you consider Oncolytics Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oncolytics Biotech wasn't on the list.
While Oncolytics Biotech currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
